miRecule, Inc.

miRecule, Inc. is a biopharmaceutical startup focusing on RNA therapeutics with a strong emphasis on personalized medicine. Established in 2016 in the United States, they are committed to developing innovative RNA-based treatments, particularly for Head & Neck Squamous Cell Carcinoma (HNSCC) and Facioscalpulohumeral Muscular Dystrophy (FSHD). Their unique approach involves leveraging genomic patient data to craft tailored therapeutics, ensuring the right drug for the right patient. The DREAmiR™ platform is their proprietary tool, utilizing genomic and outcome data from thousands of patients to identify genetic abnormalities and then devising novel RNA therapeutics to directly target and rectify these anomalies. In their most recent funding round in May 2021, miRecule secured a $5.70M investment from a consortium of investors including Alexandria Venture Investments, Alumni Ventures Blockchain Fund, Boutique Venture Partners, Pathway Bioventures, University System of Maryland Momentum Fund, and the FSHD Society.